本文選題：增生性玻璃體視網(wǎng)膜疾病 + 缺氧誘導因子-1α�。� 參考：《天津醫(yī)科大學》2011年碩士論文

【摘要】：目的： 1.定量檢測增生性糖尿病視網(wǎng)膜病變(proliferative diabetic retinopathy,PDR)、增生性玻璃體視網(wǎng)膜病變(proliferative vitreoretinopathy,PVR)及正常對照組玻璃體缺氧誘導因子-1α(Hypoxia-inducible factor 1α, HIF-1α)的質(zhì)量濃度,分析HIF-1α的變化規(guī)律。 2.分析增生性玻璃體視網(wǎng)膜疾病患者玻璃體HIF-1α表達的影響因素。 3.探討HIF-1α在增生性玻璃體視網(wǎng)膜疾病發(fā)病機制中的作用。 方法： 在常規(guī)玻璃體切除術(shù)過程中收集玻璃體待測標本,實驗組共69例71眼,其中包括PDR組37例391眼和PVR組32例32眼；正常對照組8例8眼,為本院行角膜移植術(shù)后供體眼玻璃體標本。采用酶聯(lián)免疫吸附測定法(enzyme-linked immunosorbent assay, ELISA)檢測受檢眼玻璃體中HIF-1α的質(zhì)量濃度。 結(jié)果： 1.PDR組、PVR組與正常對照組玻璃體中HIF-1α質(zhì)量濃度分別為(301.63±23.18)、(284.88±24.42)、(16.38±3.56)mg/L,三組比較差異有統(tǒng)計學意義(F=273.72,P=0.00),其中PDR組玻璃體HIF-1α質(zhì)量濃度高于正常對照組,差異有統(tǒng)計學意義(t=23.32,P=0.00),PVR組玻璃體HIF-1α質(zhì)量濃度高于正常對照組,差異有統(tǒng)計學意義(t=21.74,P=0.00),PDR組玻璃體HIF-1α質(zhì)量濃度高于PVR組,差異有統(tǒng)計學意義(t=3.01,P=0.00)。 2.PDR組Ⅳ期、Ⅴ期、Ⅵ期玻璃體中HIF-1α質(zhì)量濃度分別為(274.58±30.05)、(298.37±17.34)、(315.94±18.30)mg/L,三期比較差異有統(tǒng)計學意義(F=8.87,P=0.00),其中V期玻璃體HIF-1α質(zhì)量濃度高于Ⅳ期,差異有統(tǒng)計學意義(t=-2.44,P=0.02),Ⅵ期玻璃體HIF-1α質(zhì)量濃度高于Ⅴ期,差異有統(tǒng)計學意義(t=2.59,P=0.01),Ⅵ期玻璃體HIF-1α質(zhì)量濃度高于Ⅳ期,差異有統(tǒng)計學意義(t=4.08,P=0.00)。 3.PVR組C級、D級玻璃體中HIF-1α質(zhì)量濃度分別為(267.44±22.45)、(295.34±19.33)mg/L,D級玻璃體HIF-1α質(zhì)量濃度高于C級,差異有統(tǒng)計學意義(t=3.72,P=0.00)。 4.實驗組中合并腎病與不合并腎病組玻璃體HIF-1α質(zhì)量濃度分別為(302.69±21.65)、(292.50±25.44)mg/L,差異無統(tǒng)計學意義(P=0.22)。 5.實驗組中合并高血壓與不合并高血壓組玻璃體HIF-1α質(zhì)量濃度分別為(293.54±28.03)、(294.40±23.32)mg/L,差異無統(tǒng)計學意義(P=0.89)。 6.實驗組玻璃體HIF-1α質(zhì)量濃度與眼病史之間行線性回歸分析,可得到回歸方程Y=1.096X+286.613,故增生性玻璃體視網(wǎng)膜疾病患者玻璃體HIF-1α質(zhì)量濃度與眼病史之間關聯(lián)性較弱。 7.實驗組玻璃體HIF-1α質(zhì)量濃度與年齡、性別之間無相關性(r=-0.207,P=0.08；r=0.016,P=0.89),與術(shù)前空腹血糖水平、糖尿病病程也無相關性(r=-0.159,P=0.33,r=0.012,P=0.94)。 結(jié)論： 1.增生性玻璃體視網(wǎng)膜疾病患者玻璃體HIF-1α質(zhì)量濃度比正常人明顯升高,并且HIF-1α質(zhì)量濃度隨眼底病變程度加重而升高。 2.HIF-1α可能在增生性玻璃體視網(wǎng)膜疾病發(fā)病機制中起一定作用。
[Abstract]:Objective: 1. The mass concentrations of proliferative diabetic retinopathy (HIF-1 偽) in proliferative diabetic retinopathy (PVR) and hypoxia-inducible factor 1 偽 (HIF-1 偽) in vitreous hypoxia inducible factor 1 偽 (HIF-1 偽) in normal control group and proliferative retinopathy vitreoretinopathy proliferative vitreoretinopathy (PVR) were measured quantitatively, and the changes of HIF-1 偽 were analyzed. 2. To analyze the influencing factors of HIF-1 偽 expression in vitreous body of proliferative vitreoretinopathy patients. 3. To investigate the role of HIF-1 偽 in the pathogenesis of proliferative vitreoretinal diseases. Methods: Vitreous specimens were collected during routine vitrectomy. There were 69 cases (71 eyes) in experimental group, including 37 cases (391 eyes) in PDR group and 32 eyes (32 eyes) in PVR group, and 8 cases (8 eyes) in normal control group. The vitreous specimen of donor eyes after keratoplasty was performed in our hospital. Enzyme linked immunosorbent assay (Elisa) was used to detect the mass concentration of HIF-1 偽 in vitreous of eyes. Results: The mass concentrations of HIF-1 偽 in vitreous of 1.PDR group and normal control group were 301.63 鹵23.18 ~ 284.88 鹵24.42 mg / L, respectively. The differences among the three groups were statistically significant (P < 0.05). The content of HIF-1 偽 in vitreous of PDR group was higher than that of normal control group, and the content of HIF-1 偽 in vitreous tissue of PDR group was higher than that of normal control group. The content of HIF-1 偽 in vitreous body was significantly higher in HIF-1 group than that in normal control group (P < 0.05), and the concentration of HIF-1 偽 in vitreous body in group B was significantly higher than that in group PVR (P < 0.05), and there was significant difference in the concentration of HIF-1 偽 in vitreous body between the two groups (P < 0.05), and the concentration of HIF-1 偽 in vitreous tissue was significantly higher than that in group PVR (P < 0.05). In 2.PDR group, the concentration of HIF-1 偽 in vitreous of stage 鈪，

本文編號：1907174